---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-008131"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:12:53.490076+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M

## Summary
- Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).
- FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.
- 2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.
- NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.
- DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02).

## SEC filing metadata
- accession: 0001628280-25-008131
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/0001628280-25-008131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/cort-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-008131
- JSON: https://secwatch.observer/filing/0001628280-25-008131.json
- Plain text: https://secwatch.observer/filing/0001628280-25-008131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.